Comparative Pharmacology
Head-to-head clinical analysis: ARZERRA versus LEQEMBI IQLIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARZERRA versus LEQEMBI IQLIK.
ARZERRA vs LEQEMBI IQLIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
None Documented
None Documented
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route.
Category C
Category C
Antineoplastic, Monoclonal Antibody
Monoclonal Antibody